Top 50 hypotheses ranked by scientific merit across 10 dimensions
| # | Hypothesis | Score | Dimensions | Price Trend | Market | Debates |
|---|---|---|---|---|---|---|
| 🥇 |
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
mechanistic
• TREM2
• neurodegeneration
|
0.990 |
Nov
0.72 Feas
0.82 Imp
0.78 Drug
0.65 |
0.870 | 3 | |
| 🥈 |
TREM2-Dependent Microglial Senescence Transition
mechanistic
• TREM2
• neurodegeneration
|
0.950 |
Nov
0.78 Feas
0.72 Imp
0.91 Drug
0.65 |
0.968 | 3 | |
| 🥉 |
Chromatin Remodeling-Mediated Nutrient Sensing Restoration
mechanistic
• SMARCA4
• neurodegeneration
|
0.914 |
Nov
0.72 Feas
0.92 Imp
0.82 Drug
0.90 |
0.924 | 3 | |
| 4 |
SASP-Mediated Complement Cascade Amplification
mechanistic
• C1Q/C3
• neurodegeneration
|
0.910 |
Nov
0.85 Feas
0.75 Imp
0.80 Drug
0.85 |
0.931 | 2 | |
| 5 |
TREM2-ASM Crosstalk in Microglial Lysosomal Senescence
mechanistic
• SMPD1
• neurodegeneration
|
0.910 |
Nov
0.70 Feas
0.80 Imp
0.76 Drug
0.65 |
0.790 | 3 | |
| 6 |
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration
mechanistic
• TREM2
• neurodegeneration
|
0.907 |
Nov
0.72 Feas
0.82 Imp
0.78 Drug
0.65 |
0.813 | 3 | |
| 7 |
Nutrient-Sensing Epigenetic Circuit Reactivation
mechanistic
• SIRT1
• neurodegeneration
|
0.907 |
Nov
0.70 Feas
0.95 Imp
0.85 Drug
0.90 |
0.835 | 3 | |
| 8 |
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
mechanistic
• SIRT1
• neurodegeneration
|
0.895 |
Nov
0.70 Feas
0.80 Imp
0.76 Drug
0.65 |
0.831 | 3 | |
| 9 |
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
mechanistic
• TREM2
• neurodegeneration
|
0.892 |
Nov
0.72 Feas
0.68 Imp
0.82 Drug
0.45 |
0.772 | 3 | |
| 10 |
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodege
mechanistic
• NLRP3, CASP1, IL1B, PYCARD
• neurodegeneration
|
0.888 |
Nov
0.00 Feas
0.00 Imp
0.00 Drug
0.90 |
0.914 | 1 | |
| 11 |
Transcriptional Autophagy-Lysosome Coupling
mechanistic
• FOXO1
• neurodegeneration
|
0.882 |
Nov
0.80 Feas
0.75 Imp
0.78 Drug
0.70 |
0.900 | 2 | |
| 12 |
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration
mechanistic
• TREM2
• neurodegeneration
|
0.880 |
Nov
0.75 Feas
0.68 Imp
0.82 Drug
0.45 |
0.921 | 4 | |
| 13 |
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration
mechanistic
• TREM2
• neurodegeneration
|
0.875 |
Nov
0.75 Feas
0.68 Imp
0.82 Drug
0.45 |
0.918 | 3 | |
| 14 |
GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Clearance
mechanistic
• GRIN2B
• neuroscience
|
0.869 |
Nov
0.00 Feas
0.00 Imp
0.00 Drug
0.95 |
0.749 | 3 | |
| 15 |
TREM2-Mediated Cholesterol Dysregulation in Microglial Senescence
mechanistic
• CYP46A1
• neurodegeneration
|
0.869 |
Nov
0.78 Feas
0.65 Imp
0.75 Drug
0.58 |
0.891 | 3 | |
| 16 |
ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia
mechanistic
• ACSL4
• Alzheimer's Disease
|
0.847 |
Nov
0.85 Feas
0.75 Imp
0.85 Drug
0.00 |
0.860 | 3 | |
| 17 |
Microglial AIM2 Inflammasome as the Primary Driver of TDP-43 Proteinopat
mechanistic
• AIM2, CASP1, IL1B, PYCARD, TARDBP
• neurodegeneration
|
0.824 |
Nov
0.00 Feas
0.00 Imp
0.00 Drug
0.90 |
0.863 | 1 | |
| 18 |
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Agg
mechanistic
• NLRP3, CASP1, IL1B, PYCARD
• neurodegeneration
|
0.822 |
Nov
0.00 Feas
0.00 Imp
0.00 Drug
0.90 |
0.716 | 1 | |
| 19 |
IL-6 Trans-Signaling Blockade at the Oligodendrocyte-Microglia Interface
mechanistic
• IL6R, IL6
• neuroinflammation
|
0.806 |
Nov
0.65 Feas
0.72 Imp
0.80 Drug
0.85 |
0.739 | 1 | |
| 20 |
Mitochondrial DAMPs-Driven AIM2 Inflammasome Activation in Neurodegenera
mechanistic
• AIM2, CASP1, IL1B, PYCARD
• neurodegeneration
|
0.805 |
Nov
0.00 Feas
0.00 Imp
0.00 Drug
0.90 |
0.775 | 1 | |
| 21 |
Calcium-Dysregulated mPTP Opening as an Alternative mtDNA Release Mechan
mechanistic
• AIM2, CASP1, IL1B, PYCARD, PPIF
• neurodegeneration
|
0.804 |
Nov
0.00 Feas
0.00 Imp
0.00 Drug
0.90 |
0.774 | 1 | |
| 22 |
Prime Editing Precision Correction of APOE4 to APOE3 in Microglia
mechanistic
• APOE
• neurodegeneration
|
0.803 |
Nov
0.80 Feas
0.65 Imp
0.85 Drug
0.80 |
0.683 | 3 | |
| 23 |
Mitochondrial DNA-Driven AIM2 Inflammasome Activation in Neurodegenerati
mechanistic
• AIM2, CASP1, IL1B, PYCARD
• neurodegeneration
|
0.803 |
Nov
0.00 Feas
0.00 Imp
0.00 Drug
0.90 |
0.683 | 1 | |
| 24 |
ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drives White Matt
mechanistic
• ACSL4
• Alzheimer's Disease
|
0.801 |
Nov
0.00 Feas
0.00 Imp
0.00 Drug
0.00 |
0.710 | 3 | |
| 25 |
40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Sele
mechanistic
• ACSL4
• Alzheimer's Disease
|
0.801 |
Nov
0.00 Feas
0.00 Imp
0.00 Drug
0.00 |
0.756 | 4 | |
| 26 |
SASP-Driven Microglial Metabolic Reprogramming in Synaptic Phagocytosis
mechanistic
• HK2/PFKFB3
• neurodegeneration
|
0.796 |
Nov
0.80 Feas
0.70 Imp
0.75 Drug
0.85 |
0.936 | 2 | |
| 27 |
Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)
mechanistic
• APOE
• neurodegeneration
|
0.795 |
Nov
0.90 Feas
0.20 Imp
0.70 Drug
0.60 |
0.746 | 2 | |
| 28 |
Targeting SASP-Complement Amplification Through HIF-1α Downstream Effect
mechanistic
• C1QA, C1QB, C3, IL1B
• neurodegeneration
|
0.793 |
Nov
0.65 Feas
0.78 Imp
0.75 Drug
0.82 |
0.771 | 1 | |
| 29 |
Competitive APOE4 Domain Stabilization Peptides
mechanistic
• APOE
• neurodegeneration
|
0.784 |
Nov
0.80 Feas
0.20 Imp
0.60 Drug
0.30 |
0.803 | 2 | |
| 30 |
SASP-Driven Aquaporin-4 Dysregulation
mechanistic
• AQP4
• neurodegeneration
|
0.782 |
Nov
0.65 Feas
0.60 Imp
0.72 Drug
0.65 |
0.798 | 2 | |
| 31 |
LPCAT3-Mediated Lands Cycle Remodeling as the Primary Ferroptotic Primin
mechanistic
• LPCAT3
• Alzheimer's Disease
|
0.779 |
Nov
0.00 Feas
0.00 Imp
0.00 Drug
0.00 |
0.820 | 3 | |
| 32 |
TFEB Nuclear Translocation to Reset Lysosomal-Hypoxia Axis
mechanistic
• TFEB, MTOR
• neurodegeneration
|
0.779 |
Nov
0.70 Feas
0.65 Imp
0.68 Drug
0.60 |
0.682 | 1 | |
| 33 |
ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes
mechanistic
• ACSL4
• Alzheimer's Disease
|
0.779 |
Nov
0.00 Feas
0.00 Imp
0.00 Drug
0.00 |
0.820 | 3 | |
| 34 |
ALOX15-Driven Enzymatic Ferroptosis in AD Oligodendrocytes via PUFA-PE P
mechanistic
• ALOX15
• Alzheimer's Disease
|
0.777 |
Nov
0.00 Feas
0.00 Imp
0.00 Drug
0.00 |
0.819 | 3 | |
| 35 |
LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Substrate Pools
mechanistic
• LPCAT3
• Alzheimer's Disease
|
0.776 |
Nov
0.00 Feas
0.00 Imp
0.00 Drug
0.00 |
0.667 | 3 | |
| 36 |
LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability i
mechanistic
• LPCAT3
• Alzheimer's Disease
|
0.770 |
Nov
0.00 Feas
0.00 Imp
0.00 Drug
0.00 |
0.659 | 3 | |
| 37 |
APOE4 Allosteric Rescue via Small Molecule Chaperones
mechanistic
• APOE
• neurodegeneration
|
0.765 |
Nov
0.90 Feas
0.30 Imp
0.80 Drug
0.40 |
0.786 | 2 | |
| 38 |
SASP-Mediated Cholinergic Synapse Disruption
mechanistic
• MMP2/MMP9
• neurodegeneration
|
0.763 |
Nov
0.75 Feas
0.65 Imp
0.65 Drug
0.60 |
0.782 | 2 | |
| 39 |
Circadian Clock-Autophagy Synchronization
mechanistic
• CLOCK
• neurodegeneration
|
0.763 |
Nov
0.65 Feas
0.60 Imp
0.70 Drug
0.55 |
0.783 | 2 | |
| 40 |
Cell-Type Specific TREM2 Upregulation in DAM Microglia
mechanistic
• TREM2
• Alzheimer's Disease
|
0.761 |
Nov
0.65 Feas
0.70 Imp
0.75 Drug
0.75 |
0.780 | 3 | |
| 41 |
Multi-Modal Stress Response Harmonization
mechanistic
• NR3C1/CRH/TNFA
• neurodegeneration
|
0.756 |
Nov
0.70 Feas
0.70 Imp
0.70 Drug
0.80 |
0.774 | 2 | |
| 42 |
GFAP-Positive Reactive Astrocyte Subtype Delineation
mechanistic
• GFAP
• Alzheimer's Disease
|
0.754 |
Nov
0.60 Feas
0.65 Imp
0.70 Drug
0.60 |
0.772 | 3 | |
| 43 |
Astrocyte C3aR Signaling as Bifurcation Point for A1/A2 Fate
mechanistic
• C3, C3aR, NFKB1, PPARGC1A
• Alzheimer's disease, Parkins
|
0.750 |
Nov
0.50 Feas
0.50 Imp
0.50 Drug
0.00 |
no data | 0.500 | 1 |
| 44 |
TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming
mechanistic
• TREM2, CSF1R
• neurodegeneration
|
0.748 |
Nov
0.70 Feas
0.80 Imp
0.76 Drug
0.65 |
0.898 | 3 | |
| 45 |
Metabolic NAD+ Salvage Pathway Enhancement Through NAMPT Overexpression
mechanistic
• NAMPT
• neurodegeneration
|
0.745 |
Nov
0.68 Feas
0.84 Imp
0.77 Drug
0.90 |
0.815 | 3 | |
| 46 |
TREM2-SIRT1 Metabolic Senescence Circuit in Microglial Aging
mechanistic
• TREM2
• neurodegeneration
|
0.744 |
Nov
0.70 Feas
0.80 Imp
0.76 Drug
0.65 |
0.905 | 3 | |
| 47 |
APOE Isoform Expression Across Glial Subtypes
mechanistic
• APOE
• Alzheimer's Disease
|
0.743 |
Nov
0.60 Feas
0.55 Imp
0.60 Drug
0.50 |
0.692 | 3 | |
| 48 |
BACE1/NRG1 Axis Dysfunction Drives Excitatory/Inhibitory Imbalance via P
mechanistic
• NRG1/ERBB4
• neurodegeneration
|
0.743 |
Nov
0.65 Feas
0.58 Imp
0.62 Drug
0.45 |
0.732 | 1 | |
| 49 |
Smartphone-Detected Motor Variability Correction
mechanistic
• DRD2/SNCA
• neurodegeneration
|
0.742 |
Nov
0.60 Feas
0.80 Imp
0.50 Drug
0.90 |
0.687 | 2 | |
| 50 |
Senescent Cell Mitochondrial DNA Release
mechanistic
• CGAS/STING1/DNASE2
• neurodegeneration
|
0.742 |
Nov
0.85 Feas
0.45 Imp
0.60 Drug
0.40 |
0.763 | 2 |